Skip to main content

Table 2 Univariate analysis

From: Serum HER2 extra-cellular domain, S100ß and CA 15-3 levels are independent prognostic factors in metastatic breast cancer patients

Parameter Median OS in months (CI 95 %) P-value
Initial characteristics
 Tumor biology group   <0.001
  HER2+ HR+ 32.1 (16.5 – NC)  
  HER2+ HR- 28.7 (19.1–34.5)  
  HER2- HR+ 12.5 (10.4–22.8)  
  Triple negative 7.6 (4.6–10.4)  
 ER status   0.087
  Negative 13.3 (10.0–19.1)  
  Positive 20.1 (12.4–20.6)  
 PR status   0.035
  Negative 12.5 (10.6–17.8)  
  Positive 22.8 (16.5–35.6)  
 HER2 status   <0.001
  Negative 10.4 (8.5–12.5)  
  Positive 31.6 (20.2–34.5)  
 Histological subtype   0.344
  Ductal carcinoma 15.2 (11.6–20.6)  
  All other subtypes 20.1 (10.1–35.6)  
 Histological grade (SBR)   0.024
  1 or 2 20.6 (14.8–31.6)  
  3 11.1 (9.7–15.5)  
 Inflammatory BC   0.523
  No 15.1 (11.6–20.2)  
  Yes 20.9 (6.8 – NC)  
 Metastatic status at BC diagnosis   0.012
  M0 13.6 (10.4–16.5)  
  M1 27.2 (13.7–32.1)  
Characteristics at the time of the serum sample
 Age group   0.723
  < 50 15.0 (10.0–23.0)  
  50 to 70 16.3 (11.6–20.7)  
  > 70 20.2 (9.7–51.4)  
 ECOG status   <0.001
  Score 0 34.5 (20.9–53.4)  
  Score 1 16.5 (12.1–22.5)  
  Score 2 8.5 (3.8–16.8)  
  Score 3 2.0 (1.4–4.6)  
 Number of lines of CT   <0.001
  0 line 17.6 (14.8–27.2)  
  1 or 2 line(s) 22.8 (16.8–32.1)  
  > 2 lines 6.4 (4.6–10.4)  
 Previous anti-HER2 treatment   <0.001
  No 11.7 (9.8–15.2)  
  Yes 28.7 (20.1–33.9)  
 Metastatic-free interval   0.464
  ≤ 24 months 14.8 (10.6–20.7)  
  > 24 months 16.5 (12.4–23.3)  
 Number of metastatic sites   <0.001
  1 59.2 (23.0 – NC)  
  > 2 13.3 (11.1–16.8)  
 Location of metastatic sites   0.001
  Bone and/or subcutaneous only 63.6 (95 % CI NC)  
  Visceral 14.4 (11.4–19.4)  
 Brain metastases   <0.001
  Absent 30.4 (17.2–34.9)  
  Present 9.7 (5.6–10.4)  
 Liver metastases   <0.001
  Absent 28.7 (14.9–36.8)  
  Present 12.4 (10.6–17.6)  
 Bone metastases   0.639
  Absent 17.8 (10.6–31.6)  
  Present 15.2 (12.1–20.2)  
 Lung metastases   0.096
  Absent 20.7 (14.4–30.4)  
  Present 12.4 (10.1–17.8)  
 Lymph node metastases   0.296
  Absent 19.4 (12.4–27.7)  
  Present 13.6 (10.5–19.1)  
 Subcutaneous metastases   0.006
  Absent 19.4 (13.7–22.8)  
  Present 11.3 (4.7–15.2)  
 Pleural metastases   0.077
  Absent 16.3 (12.5–20.9)  
  Present 13.3 (5.2–28.7)  
 Metastases of other sites   <0.001
  Absent 20.9 (16.2–30.7)  
  Present 11.1 (7.5–13.6)  
 Anemia   0.134
  No 15.5 (8.1–22.8)  
  Yes 10.3 (8.1–11.7)  
 Leucopenia   0.363
  No 10.3 (8.5–12.4)  
  Yes 10.8 (6.4–31.6)  
 Neutropenia   0.908
  No 10.6 (8.5–12.4)  
  Yes 10.4 (5.2 – NC)  
 Lymphopenia   0.351
  No 11.1 (9.4–15.5)  
  Yes 8.4 (4.7–10.6)  
 Thrombopenia   0.748
  No 10.6 (8.5–13.6)  
  Yes 10.1 (2.6–20.6)  
 Serum protein level   0.780
  Normal 9.7 (5.2–11.6)  
  Low 6.4 (2.3–13.6)  
 Serum albumin level   <0.001
  Normal 14.4 (11.1–19.4)  
  Low 1.6 (1.1–2.4)  
 Serum LDH   0.241
  Normal 10.3 (5.5–13.7)  
  Elevated 4.7 (1.9–9.8)  
 Elevated CEA   0.001
  Normal 20.6 (16.2–28.7)  
  Elevated 10.6 (8.7–12.5)  
 Elevated CA 15-3   <0.001
  Normal 28.7 (20.1–59.2)  
  Elevated 11.3 (9.7–14.4)  
 Serum HER2 (cut-off 15 ng/mL)   <0.001
  Normal 22.6 (16.2–32.3)  
  Elevated 11.3 (8.9–14.4)  
 Serum HER2 (cut-off 30 ng/mL)   <0.001
  Normal 20.2 (15.0–28.6)  
  Elevated 10.1 (5.2–13.6)  
 Serum NSE (cut-off 12.5 μg/L)   <0.001
  Normal 20.6 (16.2–30.4)  
  Elevated 9.9 (5.6–14.4)  
 Serum MMP9 (cut-off 50 ng/mL)   0.009
  Normal 3.8 (1.1 – NC)  
  Elevated 16.2 (12.5–20.7)  
 Serum S100ß (cut-off 0.12 μg/L)   <0.001
  Normal 17.2 (14.4–22.6)  
  Elevated 4.5 (1.6–10.0)  
 Serum S100ß (cut-off 0.072 μg/L)   <0.001
  Normal 20.3 (15.1–30.4)  
  Elevated 6.2 (4.5–12.1)  
  1. Abbreviations: ER estrogen-receptors, PR progesterone-receptors, SB Scarf, Bloom and Richardson, BC breast cancer, CT chemotherapy, LDH Lactate Deshydrogenase, CEA Carcinoembryonic Antigen, CA 15-3 Cancer Antigen 15-3, HER2-ECD HER2-extra-cellular domain, NSE Neuron Specific Enolase, MMP-9 Matrix Metalloproteinase 9